ArticleWorld journal of urology2025
Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancer.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrevious studies investigated the impact of timing between neoadjuvant therapy (NAT) and radical cystectomy (RC) (NAT-to-RC interval) on overall survival (OS). However, these studies primarily focused on neoadjuvant chemotherapy (NAC), leaving the effects of neoadjuvant immunotherapy (NAI) and chemoimmunotherapy (NACI) unexplored.
methodsWe retrospectively reviewed 717 treated with RC between 2015 and 2024 at a tertiary referral center. For the purpose of the study, patients receiving either NAC, NAI, or NACI were included. Multivariable Cox regression analysis (MCR) was used to assess the association between the NAT-to-RC interval and any cause of death. MCRs models together with the Harrell's C-index, were used to test progressively increasing weekly NAT-to-RC interval cut-offs. Kaplan-Meier analysis was used to estimate OS based on the first interval threshold significantly associated with survival outcomes.
resultsAmong 246 eligible patients, 110 (45%) received NAC, 101 (41%) NAI, and 35 (14%) NACI. The NAT-to-RC interval was 46 days (IQR: 28-71 days). Over a median follow-up of 40 months, 43 patients (17%) died from any cause. In MCR, longer NAT-to-RC intervals were significantly associated with reduced OS (per 2-week increase: Hazard ratio [HR] 1.06, p = 0.004). The first statistically significant cut-off was at 11 weeks (adjusted HR: 1.88, p = 0.048, C-index: 74%). Patients with an interval of 11 weeks or more (n = 53, 22%) had significantly lower 3-year OS than those with shorter intervals (86% vs. 75%, adjusted HR: 1.88, p = 0.048). Similar results were observed in the NAI/NACI subgroup with a 14-week cut-off (unadjusted HR: 4.27, p = 0.043, C-index: 59%).
conclusionA prolonged NAT-to-RC interval is independently associated with poorer OS, even in patients receiving NAI or NACI. An interval of 11 weeks is associated with a decline in OS, suggesting a potential time-sensitive impact of delayed RC. These findings underscore the importance of timely RC following NAT, particularly as the use of NAT strategies continues to expand.
Indexed as
Identifiers
41204965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.